Bibliografisk note

Funding Information:
The panel acknowledge the work of Klizia Marinoni and Delanie Young, from the Scientific and Medical Division at ESMO, for the project coordination and editorial assistance. No external funding has been received for the preparation of these expert consensus statement. Production costs have been covered by ESMO from central funds. IVL reports speaker honoraria (institutional) from Amgen, AstraZeneca, Pfizer/Edimark, Novartis, Sandoz outside of published work; and writing engagement from Pfizer/Edimark outside of published work, research funding (institutional): Resilience Care outside of published work; GCa is consultant for Pfizer, Roche, Novartis, Seattle Genetics, Lilly, Egetis, Kyowa, Algo Therapeutics, NuraBio, Helsinn, outside the submitted work; AC declares institutional research funding from Genentech, Merck Serono, Bristol Myers Squibb, Merck Sharp & Dohme, Roche, Beigene, Bayer, Servier, Lilly, Novartis, Takeda, Astellas, Natera, Jonhson and Jonhson and Fibrogen. Advisory board or speaker fees paid to my institution from Amgen, Merck Serono and Roche in the last 5 years. RTC is a consultant for Novartis, AstraZeneca, Genentech, Merck, Immunomedics, Puma and received honorarium from Novartis and AstraZeneca, all outside of the submitted work; GCu took part in advisory boards for Pfizer, Roche, Lilly, Ellipsis, Novartis, Daichi Sankyo and Seattle Genetics; DL has reported consultant/advisory boards for Prosonna, Alnylam, Roche, Bristol-Myers Squibb, Takeda and Novartis; EF reports consulting or advisory role or speaker's bureau for Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, F. Hoffmann–La Roche, Gsk, Janssen, Medical Trends, Merck Serono, Merck Sharp & Dohme, Peptomyc, Peervoice, Pfizer, Sanofi Genzyme, Springer, Takeda; and Independent Member of the Board for GRIFOLS; ARF reports honoraria and/or advisory board fees from Daiichi Sankyo, Gilead, Merck Sharp & Dohme, Novartis, Roche outside the submitted work; meeting/travel grants: Roche outside the submitted work. PAG reports other from Up-to-Date, grants from BCRF, from NCI/NIH, consulting income from InformeDNA, Grail and Blue Note Therapeutics, outside the submitted work; JH reports research grant support from Pfizer Ireland, outside of submitted work; CJ reports speaker honorarium from Janssen and Pfizer outside the submitted work; FJ reported advisory/consulting /lectures outside of the submitted work for Ipsen, GSK, Astra Zeneca, Janssen, Astellas, BMS, MSD, Clovis, Amgen, Seagen; grant from Astellas and BMS outside of the submitted work; KJ acted as consultant for Amgen, Hexal, Riemser, Helsinn, Voluntis Pfizer and BD Solution and received speaker honoraria from MSD, Merck, Amgen, Hexal, Riemser, Helsinn, Voluntis, Pfizer and art-tempi and OnkoUpdate; ML acted as consultant for Roche, AstraZeneca, Eli Lilly, Exact Sciences Pfizer, Seagen, MSD and Novartis and received speaker honoraria from Roche, Sandoz, Takeda, Pfizer, Eli Lilly, Ipsen and Novartis outside the submitted work and travel grants from Gilead; DL, consultant for AstraZeneca, Bristol Myers Squibb, OncXerna all outside the submitted work; HL reports advisory/consultation fees from Roche, Astra Zeneca, BMS, Merck, MSD, Novartis, Pfizer, Amgen, outside the submitted work; CL reports personal fees from PledPharma, personal fees from Disarm Therapeutics, personal fees from Asahi Kasei, personal fees from Metys Pharmaceuticals, personal fees from OnQuality, personal fees from Mitsubishi Tanabe, personal fees from NKMax, personal fees from Novartis, personal fees from HengRui, personal fees from Nuro Bio, personal fees from Osmol Therapeutics, Inc. personal fees from Grunenthal, outside the submitted work; AHP reports other from Up-to-Date, and grants from Susan G. Komen, BCRF, the V Foundation and NCI/NIH; KS reports personal fees from Adviva Heidelberg, Germany, from Hessian Society of Sports Medicine, Germany, from Institut National contre le Cancer (INCA), Paris, France, from Pierre Fabre, Freiburg, Germany, from Audi Health insurance, Ingolstadt, Germany, from Swiss Group for Clinical Research, Switzerland, from University of Vienna, Austria, from Breast Cancer Center Unna, Germany, from University of Mainz, Germany and from University of Heidelberg, Germany, all outside the submitted work; WvdG reports advisory boards from Bayer, consultancy Springworks, grants from Lilly, Novartis and. All to the institution; GPe reports grants from Amgen, grants, personal fees and non-financial support from Merck, grants and non-financial support from Astra Zeneca, grants and personal fees from Roche, grants and personal fees from Bristol Myers Squibb, grants from Lilly, grants and personal fees from MSD, grants and personal fees from Novartis, outside the submitted work; SP received education grants, provided consultation, attended advisory board meetings and/or provided lectures for AbbVie, Amgen, AstraZeneca, Bayer, Biocartis, BioInvent, Blueprint Medicines Corporation, Boehringer Ingelheim, Bristol Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F. Hoffmann-La Roche, Foundation Medicine, Illumina, Janssen, Merck Sharp & Dohme, Merck Serono, Merrimack, Novartis, PharmaMar, Pfizer, Regeneron, Sanofi, Seattle Genetics, Takeda and Vaccibody, from whom she received honoraria (all fees to institution). All other authors have declared no conflicts of interest.

Funding Information:
IVL reports speaker honoraria (institutional) from Amgen, AstraZeneca, Pfizer/Edimark, Novartis, Sandoz outside of published work; and writing engagement from Pfizer/Edimark outside of published work, research funding (institutional): Resilience Care outside of published work; GCa is consultant for Pfizer, Roche, Novartis, Seattle Genetics, Lilly, Egetis, Kyowa, Algo Therapeutics, NuraBio, Helsinn, outside the submitted work; AC declares institutional research funding from Genentech, Merck Serono, Bristol Myers Squibb, Merck Sharp & Dohme, Roche, Beigene, Bayer, Servier, Lilly, Novartis, Takeda, Astellas, Natera, Jonhson and Jonhson and Fibrogen. Advisory board or speaker fees paid to my institution from Amgen, Merck Serono and Roche in the last 5 years. RTC is a consultant for Novartis, AstraZeneca, Genentech, Merck, Immunomedics, Puma and received honorarium from Novartis and AstraZeneca, all outside of the submitted work; GCu took part in advisory boards for Pfizer, Roche, Lilly, Ellipsis, Novartis, Daichi Sankyo and Seattle Genetics; DL has reported consultant/advisory boards for Prosonna, Alnylam, Roche, Bristol-Myers Squibb, Takeda and Novartis; EF reports consulting or advisory role or speaker’s bureau for Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, F. Hoffmann–La Roche, Gsk, Janssen, Medical Trends, Merck Serono, Merck Sharp & Dohme, Peptomyc, Peervoice, Pfizer, Sanofi Genzyme, Springer, Takeda; and Independent Member of the Board for GRIFOLS; ARF reports honoraria and/or advisory board fees from Daiichi Sankyo, Gilead, Merck Sharp & Dohme, Novartis, Roche outside the submitted work; meeting/travel grants: Roche outside the submitted work. PAG reports other from Up-to-Date, grants from BCRF, from NCI/NIH, consulting income from InformeDNA, Grail and Blue Note Therapeutics, outside the submitted work; JH reports research grant support from Pfizer Ireland, outside of submitted work; CJ reports speaker honorarium from Janssen and Pfizer outside the submitted work; FJ reported advisory/consulting /lectures outside of the submitted work for Ipsen, GSK, Astra Zeneca, Janssen, Astellas, BMS, MSD, Clovis, Amgen, Seagen; grant from Astellas and BMS outside of the submitted work; KJ acted as consultant for Amgen, Hexal, Riemser, Helsinn, Voluntis Pfizer and BD Solution and received speaker honoraria from MSD, Merck, Amgen, Hexal, Riemser, Helsinn, Voluntis, Pfizer and art-tempi and OnkoUpdate; ML acted as consultant for Roche, AstraZeneca, Eli Lilly, Exact Sciences Pfizer, Seagen, MSD and Novartis and received speaker honoraria from Roche, Sandoz, Takeda, Pfizer, Eli Lilly, Ipsen and Novartis outside the submitted work and travel grants from Gilead; DL , consultant for AstraZeneca, Bristol Myers Squibb, OncXerna all outside the submitted work; HL reports advisory/consultation fees from Roche, Astra Zeneca, BMS, Merck, MSD, Novartis, Pfizer, Amgen, outside the submitted work; CL reports personal fees from PledPharma, personal fees from Disarm Therapeutics, personal fees from Asahi Kasei, personal fees from Metys Pharmaceuticals, personal fees from OnQuality, personal fees from Mitsubishi Tanabe, personal fees from NKMax, personal fees from Novartis, personal fees from HengRui, personal fees from Nuro Bio, personal fees from Osmol Therapeutics, Inc., personal fees from Grunenthal, outside the submitted work; AHP reports other from Up-to-Date, and grants from Susan G. Komen, BCRF, the V Foundation and NCI/NIH; KS reports personal fees from Adviva Heidelberg, Germany, from Hessian Society of Sports Medicine, Germany, from Institut National contre le Cancer (INCA), Paris, France, from Pierre Fabre, Freiburg, Germany, from Audi Health insurance, Ingolstadt, Germany, from Swiss Group for Clinical Research, Switzerland, from University of Vienna, Austria, from Breast Cancer Center Unna, Germany, from University of Mainz, Germany and from University of Heidelberg, Germany, all outside the submitted work; WvdG reports advisory boards from Bayer, consultancy Springworks, grants from Lilly, Novartis and. All to the institution; GPe reports grants from Amgen, grants, personal fees and non-financial support from Merck, grants and non-financial support from Astra Zeneca, grants and personal fees from Roche, grants and personal fees from Bristol Myers Squibb, grants from Lilly, grants and personal fees from MSD, grants and personal fees from Novartis, outside the submitted work; SP received education grants, provided consultation, attended advisory board meetings and/or provided lectures for AbbVie, Amgen, AstraZeneca, Bayer, Biocartis, BioInvent, Blueprint Medicines Corporation, Boehringer Ingelheim, Bristol Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F. Hoffmann-La Roche, Foundation Medicine, Illumina, Janssen, Merck Sharp & Dohme, Merck Serono, Merrimack, Novartis, PharmaMar, Pfizer, Regeneron, Sanofi, Seattle Genetics, Takeda and Vaccibody, from whom she received honoraria (all fees to institution). All other authors have declared no conflicts of interest.

Publisher Copyright:
© 2022 European Society for Medical Oncology